Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

Yuki Yoshimatsu; Noriyuki Ebi; Ryunosuke Ooi; Takuto Sueyasu; Saori Nishizawa; Miyuki Munechika; Kohei Yoshimine; Yuki Ko; Hiromi Ide; Kosuke Tsuruno; Kazunori Tobino

doi:10.2169/internalmedicine.5463-20

This article has now been updated. Please use the final version.

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

Yuki Yoshimatsu, Noriyuki Ebi, Ryunosuke Ooi, Takuto Sueyasu, Saori Nishizawa, Miyuki Munechika, Kohei Yoshimine, Yuki Ko, Hiromi Ide, Kosuke Tsuruno, Kazunori Tobino

Author information

Keywords: epidermal growth factor receptor, EGFR, tyrosine kinase inhibitor, TKI, adenosquamous, rechallenge

JOURNAL OPEN ACCESS Advance online publication

Article ID: 5463-20

DOI https://doi.org/10.2169/internalmedicine.5463-20

The final version of this article is now available: Vol. 60 (2021), No. 7 pp. 1067-1071

Details

Abstract

The efficacy of epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.

Corresponding author

Register with J-STAGE for free!